latest news releases from the newsroom
Cyclacel Pharmaceuticals, Inc.
Cyclacel Begins Phase 2 Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
BERKELEY HEIGHTS, N.J., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that the company has begun treating patients in a Phase 2, open label, single arm, multicenter clinical trial of sapacitabine (CYC682) in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy. This study builds on the observation of prolonged stable disease of four months or longer experienced by heavily pretreated NSCLC patients involved in two Phase 1 studies of sapacitabine. The multicenter Phase 2 trial is led by Philip D. Bonomi, M.D., the Alice Pirie Wirtz Professor of Medical Oncology at the Rush University Medical Center, Chicago.
Kona Grill, Inc.
Kona Grill Update Regarding Financing
SCOTTSDALE, Ariz., Jan. 13, 2009 (GLOBE NEWSWIRE) -- In connection with management's fiscal planning for 2009 and a review of its liquidity needs, Kona Grill, Inc. (Nasdaq:KONA) continues to pursue various sources of external financing to supplement its operating cash flows. Such financing could include equipment financing, a working capital facility, a bank term loan, the issuance of convertible debt, a short-term ("bridge") loan, sale of equity, an equity rights offering, or any combination of the foregoing. To implement the foregoing, the Board of Directors has established a special committee comprised of independent directors to work closely with management and the Company's outside professional advisors to identify, review and oversee the structuring, negotiation and execution of all reasonable alternatives in the best interests of the Company and its stockholders.
Questcor Pharmaceuticals to Expand Sales Force
UNION CITY, Calif., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that it is increasing its sales force from 15 representatives currently to 30 representatives in order to build upon continued positive growth trends in prescriptions of its H.P Acthar(r) Gel (repository corticotropin injection) for the treatment of exacerbations associated with multiple sclerosis ("MS"), an indication for which Acthar is already approved.